Preventive care is already funded, with most employer health plans covering screenings and annual visits. GLP-1 medications are now being incorporated into that same preventive care strategy, yet the issue remains unchanged: follow-through.

GLP-1 adherence refers to how consistently patients continue therapy over time, while discontinuation reflects how quickly treatment is abandoned. In real-world settings, approximately 46% to 65% of patients discontinue GLP-1 therapy within the first year, as reported in Discontinuation and Reinitiation of GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity

Coverage does not equal sustained engagement. That gap is where outcomes decline and employer healthcare costs begin to rise.

‍

Preventive Care Utilization Gaps in Employer Health Plans

Most preventive services are already covered and available. Despite that, completion rates remain inconsistent.

National data shows the gap clearly. Only about 8% of U.S. adults receive all recommended preventive services, according to the Agency for Healthcare Research and Quality (AHRQ).

The issue is not awareness. Employees generally understand the value of preventive care. The issue is follow-through:

• Screenings are deprioritized because they are not urgent
• Scheduling requires effort and coordination
• There is no immediate consequence for delaying care

As a result, preventive care is deferred until symptoms appear and this same utilization gap is now emerging in GLP-1 adherence.

‍

‍

The Cost Impact of GLP-1 Discontinuation for Employers

The same behavior gap now carries significantly higher cost implications.

GLP-1s are positioned as preventive intervention for obesity management and related conditions. But when adherence drops and discontinuation occurs, that preventive value erodes.

Discontinuation shifts care from early metabolic management to downstream complication treatment. That shift drives employer healthcare costs.

Without sustained GLP-1 adherence:

• Weight regain is common after stopping therapy
• Cardiometabolic risk factors return or worsen
• Progression to chronic conditions such as diabetes and cardiovascular disease accelerates

Clinical evidence suggests that continued use may be necessary to maintain benefit, as outlined in JAMA Network Open.

Chronic condition management remains a primary driver of employer healthcare costs, with obesity and related conditions among the most significant contributors.

From an employer perspective, GLP-1 discontinuation increases:

• Claims volatility
• Treatment complexity
• Long-term cost exposure

Coverage alone does not control cost. GLP-1 adherence determines whether these medications function as preventive care or become high-cost, underutilized benefits.

‍

Why Employer GLP-1 Strategies Fail to Drive Adherence

Most employer approaches to preventive care focus on awareness. Typical tactics include:

• Annual reminders
• Open enrollment messaging
• General wellness campaigns

These approaches increase visibility but do not consistently improve utilization or GLP-1 adherence. Employees may:

• Plan to engage but not follow through
• Delay due to time constraints
• Avoid care if it feels inconvenient or unclear

Without a system that drives completion and sustained engagement, participation remains inconsistent.

‍

‍

Preventive Care Requires Structure to Drive Engagement

Improving preventive care outcomes requires more than access. It requires structure that supports ongoing engagement.

Effective approaches include:

• Triggered outreach based on missed activity, not calendar timing
• Simplified access to care, reducing steps to initiate and continue treatment
• Follow-up systems when engagement drops, especially for GLP-1 therapy
• Integration with chronic condition management programs

Programs that combine access with continuous engagement and accountability produce more stable outcomes.

The eMed approach to population health follows this model by focusing on sustained engagement, not one-time access. Preventive care is treated as an ongoing process rather than a single interaction.

For employers, this reduces variability in participation and improves consistency in outcomes.

What Employers Should Do Now

Preventive care is not a coverage issue. It is an execution gap most employers are not equipped to manage on their own.

• Stop relying on eligibility as a proxy for utilization
  Coverage does not indicate engagement. Employers need reporting that reflects GLP-1 adherence and actual participation.
• Demand visibility from vendors
  Most employers cannot directly track preventive care utilization or GLP-1 adherence. That visibility must come through claims, pharmacy data, and program reporting.
• Identify where engagement breaks
  Drop-off occurs across the lifecycle, from prescription to onboarding to ongoing adherence.
• Prioritize programs that manage the full journey
  Point solutions do not solve adherence. Integrated models are required.
• Treat GLP-1s as a managed intervention
  Without active management, these medications become high-cost benefits with inconsistent use and limited impact.

The underlying issue is not coverage. It is the absence of systems that ensure care is followed and sustained.

‍

‍

What This Comes Down To

Preventive care does not fail at the point of coverage. It fails in the gap between starting care and continuing it.

GLP-1s follow the same pattern. When adherence drops and discontinuation occurs, the intervention stops functioning as preventive care and starts driving avoidable employer healthcare costs.

For employers, the priority is not expanding access. It is ensuring the care already in place is consistently used and sustained over time.

To learn more visit https://www.emed.com/for-businesses/home

‍

_Disclaimer: 

_{This content is for informational purposes only and does not constitute medical, legal, or financial advice. Third-party statistics and research cited are sourced from publicly available data and are provided for general context; results may vary by employer population. eMed's GLP-1 program pairs FDA-approved, on-label medications with clinical oversight; individual outcomes depend on a variety of factors. Employers should consult qualified advisors before making plan design or coverage decisions.}

‍